Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …

Background Patients treated with standard chemotherapy for metastatic or relapsed cervical
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …

Objectives We evaluated four different treatment regimens for advanced-stage mucinous
epithelial ovarian cancer. Methods We conducted a multicenter randomized factorial trial …

Background Platinum-based neoadjuvant chemotherapy followed by delayed primary
surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage …

Background The ICON8 study reported no significant improvement in progression-free
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …

Background The clinical benefit rate with aromatase inhibitors and the impact of treatment
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …

Background Hormonal therapies are commonly prescribed to patients with metastatic
granulosa cell tumours (GCT), based on high response rates in small retrospective studies …

Materials and methods To characterise the longitudinal clinical course of thyroid dysfunction
in patients from a single, UK regional cancer centre, a retrospective review of patients was …

Background: Taxane-induced peripheral neuropathy (TIPN) is an important cause of
premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality …

5528 Background: Advanced mEOC responds poorly to standard therapy. It comprises< 8%
pts in ovarian cancer trials, so it is difficult to examine treatment effects in this subgroup. We …